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Abstract 
Drug developing companies are forced to utilize the effective protection of the patent by 
focusing on shortening the new product introduction [NPI] process measured as Time-
to-Market [TTM].  Here the NPI process is considered and the trade-offs, which have to 
be address in the future are identified. This is done through a case study, which identi-
fies the tasks involved in the NPI process and analyzes their interdependence. The sci-
entific literature is reviewed and a series of observations from the case study are made. 
This results in an identification of the major focus areas for reducing TTM. 
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Introduction 
The pharmaceutical industry develops and produces drugs for alleviating illnesses. The 
most significant activities in the industry consist of drug development, production of the 
Active Pharmaceutical Ingredient [API] called primary production and production of the 
drug dispensing system, e.g. vials or pills called secondary production. Companies in 
the industry can perform any number of these activities in different organisational con-
stellations. Lately, increasingly more elaborate collaborations and partnerships have 
emerged. Generally speaking the industry can be divided into two groups of companies; 
drug developing companies and manufacturers of generic off-patent drugs. In this paper 
attention is given to the drug developing companies and the production of the API. Sec-
ondary production is given less attention, since it resembles traditional part production 
and the methodology from this area applies. 
 Developing and launching a new drug cost a significant amount time and money, 
since new drugs have to go through series of clinical trials prescribed by regulatory au-
thorities. These trials consist of testing the drug on cohorts of patients and monitoring 
their reaction to the drug, while other patients are given a placebo and are used as a ref-
erence group. The trials should prove not only the efficacy of the drug, but also find 
possible side effects and the pharmacokinetic properties of the drug etc. Each country 
has its own authority, which need to approve the drug. Best known is the Food and 
Drug Administration [FDA] in the US. In Europe there are three ways of getting an ap-
proval. Either the authorisation is coordinated by the European Medicines Agency 
[EMEA], which forces approvals in one member country to apply in another. Else the 
company can try to get the drug approved in one country and thereafter get others to 
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mutual recognise that approval or the company can just get it approved in each individ-
ual country. Common for all authorities in all countries is that they need to approve the 
drug before it can be sold in the respective countries. Depending on the results of the 
clinical trials they may approve the drug, reject it or require more trials or other changes 
thereby delaying the launch of the product.  
 The development of a new drug requires significant capital investments, has a high 
risk of failure and takes many years to complete. According to (DiMasi, 2002), the av-
erage cost is 802 million US$ for developing a new drug, which has a 21.9 % chance of 
getting through the process and takes 11.9 years to develop. Hence, it is most often large 
pharmaceutical companies or groups of smaller companies who enter this process. The 
risk is worth running, since the patent protection of the drug offers a time-limited mar-
ket monopoly. Patents last for 20 years and are normally filed after the discovery of the 
drug. As 11.9 years are spent on developing it, only 8 years of effective market monop-
oly are left. When the patent expires cheaper generic substitutes are readily available 
and sales suffer as a consequence. Getting the new drug into the market sooner thereby 
making better use of the patent protection is the best way for the developing companies 
to increase the total lifecycle revenue of a drug. Therefore pharmaceutical companies 
are focusing their efforts on reducing the Time-to-Market [TTM] of their new drugs.  
 In the next section the research questions are outlined followed by a description of 
the research methodology. A case study carried out in a drug developing company is 
described which was used to analyse the activities involved in the new product introduc-
tion process. This resulted in a project network, which shows the structure of the proc-
ess. Afterwards the literature and its relation to new product introduction process are 
described and finally a series of observations from the industry are stated. 
 
Research Question and Methodology 
First an overview of the new product introduction process is needed, which is the reason 
for the first research question. 
 
What major tasks are involved in the new product introduction process in the pharma-
ceutical industry and how are they interrelated? 
Research Question 1 [RQ1]: 
 
 The aim is to define a generic set of tasks including precedence relationships for 
identification of the critical activities. This identification is done on the basis of a case 
study plus interviews from several other companies. The next step is to consider what 
previous work has already been reported in the scientific literature. 
 
How does the scientific literature relate to the new product introduction process in the 
pharmaceutical industry? 
Research Question 2 [RQ2]: 
 
 The central question, which remains to be answered relates to how the TTM can be 
improved and which processes to focus on. During the interviews with managers a se-
ries of observations were made, which may clarify this. 
 
Which tasks have to be addressed to reduce Time-to-Market for the entire new product 
introduction process? 
Research Question 3 [RQ3]: 
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Sample Selection 
The main data input for this article comes from a series of interviews done with manag-
ers from the industry. Due to the large size of pharmaceutical companies and number of 
people involved in the new product introduction process, managers from a variety of 
functions such as R&D, Production, Supply Chain functions, Regulatory Affairs and 
Marketing have been interviewed to obtain a complete picture of the process. Only from 
one company, the case study company, have all managers in these positions been inter-
viewed. This case company forms the centre, but as stated in (Eisenhardt, 1989), more 
cases are needed to prove generality and validity. This has been achieved through con-
trol interviews for all management functions at 6 other companies. 
 The involved companies are all located in the greater Copenhagen and Malmo area in 
Zealand, Denmark and South Sweden. This area is known as Medicon Valley for its 
high density of pharmaceutical and biotech companies. These companies were chosen in 
part due to their geographical location close to the university and in part for their will-
ingness to participate in the interviews. 
 
Interview Protocol 
As the nature of this project is exploratory, the form of a semi-structured interview was 
chosen. In this interview form, a structured list of questions is prepared in advance. But 
during the interview the interviewer can skip some questions and go in depth with oth-
ers, depending on how the interview evolves. This is suitable as it helps keeping track of 
the interview, while allowing the interviewer to explore interesting new statements of-
fered by the interviewee. Since most managers’ working knowledge of the involved 
planning and execution of tasks in the new product introduction process was normally 
confined to a few tasks within their own responsibility area, it made no sense to spend 
much time on probing for answers outside their respective area of interest. 
 After a short discussion of the managers’ responsibility area, he/she was asked to 
identify important tasks in the new product introduction process and point to major bot-
tlenecks and problems in the process. This was done on the basis of a project network 
structure, which was iteratively developed throughout the interviews. With this informa-
tion it was also possible to find the tasks that prolong the market introduction and lead 
to an unnecessarily high TTM. 
 Afterwards questions to all tasks in the process were posed and the manager an-
swered as best he/she could. This served to establish knowledge of the tasks the man-
ager worked with or was responsible for and observations of weak practices were made.  
 
Data Collection 
All the interviews were conducted from December 2009 to March 2010 and in all 14 
managers from 7 companies have been interviewed. All interviews were digitally re-
corded for later use and sketches of how to improve the project network were gathered 
from the interviews. Validity and reliability was ensured by having control interviews 
for each manager position type as mentioned in ‘Sample Selection’.  
 
Case Study 
The case study builds on interviews and information gathered from a pharmaceutical 
company, which for confidentiality reasons shall remain nameless. The company is a 
drug developing pharmaceutical company, which develops and manufactures a range of 
APIs and final drugs. All drugs are of similar chemical structure and are produced at 
several multi-purpose batch plants in Europe. The R&D organisation including a pilot 
plants use up more than 20 % of the annual revenue. In all 8 managers from across the 
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organisation were interviewed such that the complete new product introduction process 
in the company was covered.  
 The new product introduction process is organised in a classic matrix structure, 
which, as became apparent from interviewing the other reference companies, is com-
monly used in the industry. After the development of a series of new compounds, the 
most promising are chosen to be further developed and get assigned to a development 
team. The development team consists of specialists from the different functions in the 
company i.e. production, R&D, marketing and regulatory affairs. The team’s composi-
tion depends on the stage in the new product introduction process of the drug. Market-
ing is involved in the beginning and end of the process to evaluate economic feasibility 
and prepare forecasts. Production and Supply Chain managers are increasingly in-
volved, the further along the project proceeds, starting during capacity planning and the 
design of the production process. Under the responsibility of the R&D department, the 
production of prototype API for the clinical trials is done in the pilot plants, which are 
not intended for large scale production. Both R&D and Regulatory Affairs are involved 
all the way from conception of the drug to final approval. Decisions on whether to con-
tinue the development of the drug are taken on revision meetings with the top manage-
ment. 
 
Identifying the Project Network 
During all interviews, a project network of the new product introduction process was 
presented and each interviewee was then asked to suggest changes in how they per-
ceived the project network structure. Through this iterative process the project network 
seen in Figure 1 was created. The project network involves three key functions in the 
company (R&D, Production and Marketing) and those activities carried out by the 
Regulatory Authorities. The length of the tasks in Figure 1 is not indicative of the task 
lengths or the resource consumption, but helps indicating the timeline in the process 
from patent filing to patent expiration.  
 
 
Figure 1 - Project network representation of the new product introduction process. NB: Task 
 length does not represent task duration. 
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 The tasks of the Regulatory Authorities are found at top of the network. R&D and 
Regulatory Affairs make up the R&D category. Here the first main task is the concep-
tion of the drug itself (cf. the R&D task). It is at this time the application for the patent 
is filed and the patent life starts (cf. the filing and expiration events). Next, initial stud-
ies of the drug are made in the pre-clinical trials (cf. the PC task). Based on the animal 
experiments in the pre-clinical trial, the documentation is sent to the authorities, here 
illustrated for the FDA, for review (cf. the first R task) as an Investigational New Drug 
application [IND]. If it is approved, the company can start the clinical trials (cf. the C1-
C3 tasks). After these have been completed, documentation is sent as a New Drug Ap-
plication [NDA] (cf. the event NDA) for a final review (cf. the second R task). The drug 
can either be completely rejected, completely approved or the authority can request 
more data thereby delaying the approval. This will require the company to respond to 
any comments from the authority and possibly produce the requested data (cf. task RR) 
before final review and the approval can be given (cf. the task R and the event Ap-
proval). A final clinical trial may also be needed after the approval of the drug, if the 
authorities or company sees the need for one. This could for instance be to try the drug 
on smaller patient segments such as children or pregnant women. Though the authori-
ties’ requirements are difficult to live up to, they are generally clearly stated as guide-
lines. The uncertainty of approval arises from the company’s interpretation of these 
guidelines. The uncertainty of the trials comes from the difficulty of predicting how 
patients respond to the drug. These uncertainties are a clear risk for all tasks carried out 
parallel to the clinical trial. If a trial fails, prepared capacity becomes idle and work on 
other tasks become worthless. In the worst case the entire drug is abandoned or rejected 
and the company has nothing to show for its investment. 
 The production of prototype batches in pilot plants for the clinical trials (cf. the Pro-
totype Batch Prod. task) is in some companies a R&D task and a production task in oth-
ers. Production and supply chain functions are then much stronger involved during the 
design of the production process (cf. the Process Design task) which is done simultane-
ously with the clinical trials. Depending on the production method and current capaci-
ties, additional production resources may have to be made available (cf. capacity prepa-
ration). This could either be by clearing capacity at existing production lines or by ex-
panding production facilities with new equipment or even factories. The reason capacity 
preparations are done in advance of the process design is that it may take that a long 
time to find equipment or build a factory. For the case company all production proc-
esses are so similar, that the same equipment is used. Process design is often more proc-
ess tweaking than fundamental redesign. This relation between capacity preparation and 
process design may be different for other companies. The production of the drug then 
starts before the approval is gained as three high quality and identical batches have to be 
produced for the authorities (cf. the Production task). Furthermore, API inventories are 
normally filled before the market introduction (cf. the launch event) in order to fill up 
the market immediately after approval or market access has been gained. The produc-
tion continues until the drug is taken of the market. 
 In addition to forecasting and promoting the sales volume (cf. the Sales task), mar-
keting is also involved in economical assessments of a drug’s potential early in the 
process (cf. the Eco. Ass. task) and in preparing the entry into new markets (cf. the 
Market Access task). The latter task consist of further identifying the economical bene-
fit of entering the country or market but also of planning and conducting negotiations 
with local authorities to secure subsidies. As new approvals and subsidies have to be 
negotiated for each authority, this process is repeated in each country or market for each 
drug; hence the cascade in Figure 1. 
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 The remaining tasks involved in new product introduction are not shown here, since 
they consist of traditional tasks also found in other industries such as procurement and 
distribution. It is important to note, that TTM is measured from the patent filing to mar-
ket launch of the drug. This is seen in the precedence relationship identified through the 
interviews in Figure 2. The precedence relationship is illustrated as a directed graph 
going from patent filing on the left side to market launch on the right side. The structure 
of the tasks from Figure 1 is kept. All inputs enter from the left side and outputs exit 
from the right.  
 All the interviewed managers pointed to the clinical trials as the major bottleneck in 
the process. In addition it was mentioned, that several managers’ main responsibility 
was to keep their task off the critical path i.e. to not delay the process. After gaining the 
approval, it would either be the subsidy negotiations or production that would slow the 
product launch. As the project network in Figure 1 has been created and the precedence 
of the tasks set in Figure 2, RQ1 has been answered. 
 
 
Figure 2: Overview of the identified precedence relationship illustrated as a directed graph.  
 
Locating Literature in the Project Network 
As can be seen in Figure 1 marked with three dotted boxes, previous contribution in the 
literature has addressed some of the activities in the new product introduction process. 
The boxes are here drawn around the main activities they are meant to plan. These areas 
are describes later in this section. The review only covers literature for operations plan-
ning. 
 When looking for literature on reducing the TTM, only a small fraction considers the 
pharmaceutical industry. No contributions have been found by the authors, which aim at 
reducing the TTM by effectively managing the operations involved in the new product 
introduction process.  
 A large amount of work has been found in computer aided process engineering. In 
(Papageorgiou, 2009), the author describes the latest advances in supply chain manage-
ment for the entire process industry focusing on uncertainty and financial issues. More 
directly aimed at the pharmaceutical industry is (Shah, 2004). Here the current trends in 
the pharmaceutical industry are listed, which are all relevant for the new product intro-
duction process. The trends include fewer potential research compounds, shorter effec-
tive patent protection, more generic substitutes and more price focused customers and 
authorities. The main contribution of (Shah, 2004) is a classification of the major areas 
found in the literature for the pharmaceutical industry. They are: 
 
• Pipeline management or planning 
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• Capacity planning 
• Simultaneously pipeline and capacity planning 
• Production planning and scheduling 
• Process development and plant design 
• Supply chain simulation 
 
 There is given no relation to how these planning areas relate to the observed trends. 
Only first 4 planning areas are really interesting in the new product introduction context 
as can be seen in Figure 1.  
 Pipeline planning is the discipline of planning which products in the pipeline to de-
velop further in the face of uncertainty involving the approval. One of the central con-
tributions here is (Jain and Grossmann, 1999), where the authors were the first to also 
schedule the development tasks with limited resources. 
 In (Papageorgiou et al., 2001) the authors were the first to investigate the impact of 
production cost and available capacity on profitability. Their MILP model tried to cap-
ture all the business rules involved in capacity planning. But their model did not account 
for the uncertainty resulting from the clinical trials. This was later addressed in (Gatica 
et al., 2003), but here pipeline planning decisions were not included. That has only been 
done in (Maravelias and Grossmann, 2001), which is the only work to date that com-
bines pipeline and capacity planning. 
 Production planning is arguably also related to the new product introduction process, 
since the above mentioned models include some production planning elements, but only 
on very aggregate level; usually annual quantities. More specific mentioning of produc-
tion planning has not been found. Nor is the new product introduction mentioned in 
(Méndez et al., 2006) or (Shaik et al., 2006), the two most commonly cited review pa-
pers on production planning in this field.  
 It seems that there is a gap in the literature with regards to an approach for reducing 
the TTM. Though some literature treats the new product introduction process, none of 
the contributions addresses the industry’s demand for a methodology aimed at reducing 
the TTM while simultaneously considering in inherit uncertainty of the clinical trials. 
With this literature review, RQ2 has been addressed. In the next section, observations 
from the case study are stated, which highlights the challenges in reducing the TTM and 
thereby shows a way for finding new methods to reduce the TTM. 
 
Insights from the Case Study 
All interviewees pointed to the clinical trials as being the major bottleneck for the whole 
new product introduction process. The reason was that trying the drugs out on patients, 
finding and analysing the results is simply a lengthy task. During the interviews the 
managers were inquired about the current planning techniques used by the company to 
plan the clinical trials while considering the entire pipeline. The interviews revealed a 
simplistic and pragmatic approach to decision making, which consisted of identifying 
key figures, discussing risk elements and making gut feeling decisions of which drugs 
to allocate which resources for.  
 
 
 
Observation 1: Risk elements seem to be handled with gut feeling and simple meas-
ures at best. No consistent methodology is employed for pipeline management.  
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 Whereas the available planning techniques for the pharmaceutical industry have 
evolved in the literature during the last 10-20 years, it seems the industry has been slow 
to follow. More focus should be given to the implementation of such techniques. 
 In the case company, the Market Access section was involved early in the new prod-
uct introduction process as advisors. The reason for this was in part so that they could 
start preparing the sales organisation for the launch, but they were also used as consult-
ants in setting up the clinical trials. Different authorities in different countries demand 
different tests and documentation to grant their approval. The decision of whether to do 
certain trials up front to gain faster approval or whether to do these later and get the 
drug out onto a smaller number of markets fast is not trivial. To the best of our knowl-
edge this has not yet been mentioned in the literature. 
 
 
 
 So far only the two most central regulatory authorities have been mentioned, FDA 
and EMEA, but there are many more. In Europe only the approval can be granted 
through the centralised system administrated by EMEA. For negotiating a subsidy, the 
company has to carry out separate negotiations with each member country or possibly 
each municipality. This leaves a lot of negotiations to be carried out. The order in which 
these negotiations are carried out is decided based on a business case made by the com-
pany, which considers authority requirements, potential market size, potential subsidy 
and expected negotiation time. As different authorities use different techniques for 
awarding or evaluating subsidies e.g. comparison to other countries or based on produc-
tion cost, the order in which these subsidy negotiations are carried out influence the 
overall granted level of subsidies. A higher subsidy leads to higher potential price of the 
drug and increased sales i.e. higher revenue. This creates a trade-off between scheduling 
negotiations to either obtain higher subsidies or to schedule negotiations such that mar-
kets can quickly be accessed. Again, the process of scheduling market access negotia-
tions was described as being based on gut felling decisions. 
 
 
 
 In preparation for the launch of a new drug in a market, it is industry practice to build 
up stock to get the drug to the customers as fast as possible. Here planning for worst 
case scenario is widely used. However due to the poor accuracy of forecasts, even plan-
ning for a scenario based on optimistic sales scenarios may not be enough to assure suf-
ficient availability. Since the last part of the approval process often involves changes to 
the label on the package, drugs are normally not packaged before the final approval is 
granted as repacking is not allowed by the authorities. The decision whether to package 
the dug up front despite the risk or ‘risk packing’ offers the trade-off between 
potentially saving the packaging procedure after approval and reduce the step between 
approval and launch versus the risk of having to change the label and throw away the 
entire packaged inventory. Throwing the drug away is not only expensive but leads to a 
further delay of the launch if the product has be produced again. 
 
Observation 3: A systematic approach to address the trade-off between negotiating 
for a higher subsidy versus negotiating for a faster market introduction seems to be 
missing.  
Observation 2: There is no or little attention given to how market expansions and 
clinical trials should be planned simultaneously and what the effect is on the time-to-
market.  
 
 
9 
 
 
 From the observations made above, it seems that the two predominate ways of reduc-
ing the TTM. The first is to balance the planning of clinical trials with market access 
planning simultaneously. The second is to focus on planning related to the phase be-
tween approval and launch, where either the order of the subsidy negotiations or level of 
risk packing can impact TTM positively. With this conclusion, RQ3 has been answered.  
 
Conclusion 
In this contribution the new product introduction process in the pharmaceutical industry 
is studied. A project network was created in a case study followed by a precedence rela-
tionship. The literature was reviewed, but no real contribution in reducing time-to-
market for the industry was found. A series of observations were made, which ended 
with an identification of the key areas were focus should be put in the future. 
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